According to a press release issued by Dr Reddys, the agreement grants it the exclusive right to distribute Briviact in India.
Dr Reddy's CEO - Branded Markets (India and Emerging Markets), M V Ramana, said "In our endeavour to make innovative medicines accessible to patients in India, we are excited to partner with UCB India for Briviact, a novel treatment for epilepsy that will make a difference to the lives of patients living with epilepsy."
UCB Neurology Patient Value Unit, head of International Markets, Max Bricchi said "This partnership is another important step towards us providing value together to patients by making Briviact available as an additional treatment choice for epilepsy."
Epilepsy is the second most common neurological conditionand as per a recent study, an estimated 70 million people suffer from it worldwide while there are over 12 million people suffering from epilepsy in India, which contributes to nearly one-sixth of the global burden, the release said.
DR Reddys share closed at Rs 2329.80 apiece, up by 2.80 per cent over previous close on the BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)